Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate
about
Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION studyDermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study.[Methotrexate toxicity. Myths and facts].An audit of influenza and pneumococcal vaccination in rheumatology outpatients.Urinary tract infections and lupus erythematosusSevere, disseminated, life threatening herpes zoster infection in a patient with rheumatoid arthritis treated with methotrexate.Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry.TNF-α Antagonist and Infection in Rheumatoid Arthritis.[Factors associated with infection in rheumatoid arthritis].Validity of self-report of infections in a longitudinal cohort of patients with rheumatoid arthritis differs by source of report and infection severity.Increased peripheral T cell reactivity to microbial antigens and collagen type II in rheumatoid arthritis after treatment with soluble TNFalpha receptors.Serious infections with antirheumatic therapy: are biologicals worse?Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritisReduced incidence of Crohn's disease in systemic sclerosis: a nationwide population study.Methods to avoid infections in patients with inflammatory bowel disease.Do antivirals have any utility in the treatment of arthritis?No impact of concomitant methotrexate use on serious adverse event and serious infection risk in patients with rheumatoid arthritis treated with bDMARDs: a systematic literature review and meta-analysisOverview of safety of non-biologic and biologic DMARDs.Three decades of low-dose methotrexate in rheumatoid arthritis: can we predict toxicity?Practical Management of Respiratory Comorbidities in Patients with Rheumatoid Arthritis.Anti-Toxoplasma antibodies in Egyptian rheumatoid arthritis patients.Risk factors for reported influenza and influenza-like symptoms in patients with rheumatoid arthritis.Investigating methotrexate toxicity within a randomized double-blinded, placebo-controlled trial: Rationale and design of the Cardiovascular Inflammation Reduction Trial-Adverse Events (CIRT-AE) Study.Predictors of infection in rheumatoid arthritis.Reactivation of cutaneous and mucocutaneous tegumentary leishmaniasis in rheumatoid arthritis patients: an emerging problem?Risk factors of severe infections in patients with rheumatoid arthritis treated with leflunomide.Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of 7740 patients.Tumour necrosis factor inhibitor therapy and infection risk in axial spondyloarthritis: results from a longitudinal observational cohort.Central Nervous System Infections Associated with Immunosuppressive Therapy for Rheumatic Disease.Increased risk of complications following total joint arthroplasty in patients with rheumatoid arthritis.Urinary tract infections in patients with rheumatoid arthritis.Genetic risk factors for infection in patients with early rheumatoid arthritis
P2860
Q24630541-A5A96C6E-6C9B-4D92-B0D2-8604CE4B9ED3Q24816844-300D382D-AF07-41C1-A6C9-0471DCB44929Q30318490-F8759B89-55ED-43FD-B2DB-5FFF6CD50F58Q33289919-1951501B-E9E7-447E-A30E-66254870D337Q33359987-D7C96EBA-72C8-4FA7-A234-E1B1CC4BEFD9Q33567058-9E2B450F-1A00-448B-BE29-7536B7CF9B8FQ33819684-821EA1FE-5F7F-439B-8E8F-E57C15E3E82BQ33872130-401850B3-430D-45D7-B5C0-82945B975DBEQ34019646-8521E85C-7530-4757-9EDC-1FD30F0619B2Q34195402-28E06C43-7859-4A3C-B44D-6C724D0F4E0AQ35550051-FDC7CEE2-561C-4FA6-AA2B-D78684EF036BQ35638259-868B56D4-EC20-4881-9193-567E36E274C2Q35759985-4FB0CA5C-1D5B-4132-A2B8-7344EA7C0DA2Q35775371-34367794-E40F-416B-9F7A-D23989869B47Q36171733-5BA20192-6018-4A51-BBD4-D504733F3826Q36181137-6666398E-B269-45E6-91A3-EFC1CB716143Q36300250-B9981BD0-FBBB-401A-8B94-9CC32EE6FA68Q38065768-433E1F17-65A4-44D6-99F1-5436E0E13296Q38267703-B18FA0D6-A54E-4182-AC8A-0F108F763231Q38642378-74DC01F2-C488-45F9-9F80-B7EC6870D2F0Q38742606-891EBE1C-26DA-4E72-93FF-8F376C25CBAAQ40280098-23C399F0-17B7-4BFE-B06F-52B4187384FFQ40298171-F0DA6743-1A80-4C4B-90EF-4A526CAE3D01Q40629895-100DE560-B7B8-476E-8E89-CA8C6779BB86Q42347671-DA1A9608-A73D-476F-8A19-1DBC187A6CAEQ44293749-2D3D022F-093A-4891-A908-941611E8B661Q45098990-31DDDD38-7062-412D-A4DC-B32CAFEEC8F8Q45840259-7476F87D-E677-45A5-B1F2-3EF7AD7496E5Q46339578-E4CC5953-8C35-49A3-BA3D-F5A82797A184Q51115209-5871CE6D-5573-485B-BA4A-1B8C80BAB26FQ51200926-D4DD7410-4F5E-4C4C-A940-574FF0A15B20Q57332116-28627B94-CE54-4104-B7DF-FF6674E28662
P2860
Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate
description
1994 nî lūn-bûn
@nan
1994 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年学术文章
@wuu
1994年学术文章
@zh-cn
1994年学术文章
@zh-hans
1994年学术文章
@zh-my
1994年学术文章
@zh-sg
1994年學術文章
@yue
name
Infection rate and use of anti ...... itis treated with methotrexate
@ast
Infection rate and use of anti ...... itis treated with methotrexate
@en
Infection rate and use of anti ...... itis treated with methotrexate
@nl
type
label
Infection rate and use of anti ...... itis treated with methotrexate
@ast
Infection rate and use of anti ...... itis treated with methotrexate
@en
Infection rate and use of anti ...... itis treated with methotrexate
@nl
prefLabel
Infection rate and use of anti ...... itis treated with methotrexate
@ast
Infection rate and use of anti ...... itis treated with methotrexate
@en
Infection rate and use of anti ...... itis treated with methotrexate
@nl
P2093
P2860
P356
P1476
Infection rate and use of anti ...... itis treated with methotrexate
@en
P2093
A A Kruize
A van der Heide
J W Bijlsma
M J van der Veen
P2860
P356
10.1136/ARD.53.4.224
P407
P577
1994-04-01T00:00:00Z